Axumin Approval History
- FDA approved: Yes (First approved May 27th, 2016)
- Brand name: Axumin
- Generic name: fluciclovine F 18
- Dosage form: Injection
- Company: Blue Earth Diagnostics, Ltd.
- Treatment for: Diagnosis and Investigation
Axumin (fluciclovine F 18) a radioactive diagnostic agent indicated for positron emission tomography (PET) imaging in men with suspected recurrent prostate cancer.
Development History and FDA Approval Process for Axumin
|May 27, 2016||FDA Approves Axumin (fluciclovine F 18) Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.